Related Post
(Trends Wide) — Former Theranos CEO, the disgraced Elizabeth Holmes, could be released from prison nearly two years sooner than expected, according to a projected release date published by the Bureau of Prisons.
Holmes surrendered to Justice when she appeared at a Texas prison camp at the end of May, after being sentenced to 11 years and three months in prison at the end of last year. However, the online Bureau of Prisons database now reports Holmes’s expected release date as December 29, 2032, which would subtract approximately two years from her full sentence.
The discrepancy appears to be due to how the Bureau of Prisons calculates your estimated release date.
A Bureau of Prisons spokesperson told Trends Wide the agency cannot comment on the conditions of any individual inmate, but said inmates can earn good conduct time (or GCT) which is calculated on their release date. projected release. Qualified inmates are currently eligible for up to 54 days of GCT time for each year of court-imposed sentence.
In addition, inmates have other ways to earn time credits while incarcerated, the spokesperson said, noting a variety of other factors that could influence the agency’s estimated release date calculation, including an inmate’s involvement in various prison programs. These factors that go into calculating an estimated release date are not unique to Holmes’ case, but are standard practice for all inmates.
Holmes is currently serving his sentence at Camp Bryan Federal Prison, a minimum-security federal prison located approximately 100 miles (about 160 kilometers) from Houston. His request to remain free on bail while she fought to overturn his conviction was denied by an appeals court in May.
Holmes was once an icon in the world of technology, serving as an example of Silicon Valley’s limitless ambitions and potential. She is now one of the rare tech executives serving prison time after being convicted early last year on multiple charges of defrauding investors while running Theranos.
Theranos was valued at $9 billion at its peak, making Holmes a paper billionaire. The company began to unravel after a 2015 Wall Street Journal investigation reported that Theranos had only performed about a dozen of the hundreds of tests it offered using its proprietary technology and with questionable accuracy. It also came to light that Theranos relied on devices made by third parties from traditional blood testing companies rather than its own technology.
